<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565159</url>
  </required_header>
  <id_info>
    <org_study_id>430321</org_study_id>
    <secondary_id>2017-002236-17</secondary_id>
    <nct_id>NCT03565159</nct_id>
  </id_info>
  <brief_title>Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors</brief_title>
  <acronym>VACIRiSS</acronym>
  <official_title>Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VACIRiSS trial is a phase-IV, multi-centre placebo controlled randomised trial of&#xD;
      conjugate pneumococcal vaccine in adult sepsis survivors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of VACIRiSS trial is to evaluate the immunogenicity and heterologous effects of&#xD;
      single dose 13-valent conjugate pneumococcal vaccine (PCV-13) in preventing infection related&#xD;
      rehospitalisation in sepsis survivors and to collect outcome event data with necessary&#xD;
      precision to inform future definitive trial design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomised 1:1 to receive one single 0.5ml dose of active or placebo Investigational Medicinal Product at baseline.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary - Time to Event</measure>
    <time_frame>Up to 365 days</time_frame>
    <description>Comparison of the time taken for infection related rehospitalisation or death between intervention and control arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary - Precision Estimates</measure>
    <time_frame>Up to 365 days</time_frame>
    <description>Outcome event data to inform future definitive trial, including:&#xD;
- proportion of rehospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary - Precision Estimates</measure>
    <time_frame>Up to 365 days</time_frame>
    <description>- proportions of reinfections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary - Precision Estimates</measure>
    <time_frame>Up to 365 days</time_frame>
    <description>- proportions of reinfection related rehospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary - Precision Estimates</measure>
    <time_frame>Up to 365 days</time_frame>
    <description>- time to first all cause rehospitalisation and</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary - Precision Estimates</measure>
    <time_frame>Up to 365 days</time_frame>
    <description>- time to first infection requiring antibiotic therapy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory - Immune recovery patterns</measure>
    <time_frame>Day 0 (baseline) to Day 90</time_frame>
    <description>Differences between the intervention and control arms of the following:&#xD;
anti-pneumococcal antibody</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory - Immune recovery patterns</measure>
    <time_frame>Day 0 (baseline) to Day 90</time_frame>
    <description>Differences between the intervention and control arms of the following:&#xD;
B cell subsets, T cell subsets and monocyte HLA-DR and PD-1 expression), function and leukocyte transcriptome</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Prevenar 13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium chloride 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar 13</intervention_name>
    <description>Pneumococcal polysaccharide conjugate vaccine</description>
    <arm_group_label>Prevenar 13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium Chloride 0.9%</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Sodium chloride 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who meet all the following inclusion criteria are eligible to participate in the&#xD;
        trial.&#xD;
&#xD;
          -  Male or female adult patients aged 18 years or older on the date of screening for the&#xD;
             trial&#xD;
&#xD;
          -  Registered with a General Practitioner&#xD;
&#xD;
          -  Reason for admission to intensive care unit or high dependence unit (HDU) was sepsis&#xD;
&#xD;
          -  Clinical condition has improved and the patient is ready for step down to HDU or ward&#xD;
             based care in the next 24 - 48 hours&#xD;
&#xD;
          -  Provision of written informed consent by the patient OR by patient's Legal&#xD;
             Representative OR Professional Consultee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet one or more of the following will be excluded from the trial.&#xD;
&#xD;
          -  Core temperature ≥38.0°C within the past 24 hours prior to study IMP administration.&#xD;
             As with other vaccines, the administration of Prevenar 13 should be postponed in&#xD;
             subjects suffering from acute, severe febrile illness. However, the presence of a&#xD;
             minor infection, such as a cold, should not result in the deferral of vaccination.&#xD;
&#xD;
          -  Hypersensitivity reaction (e.g., anaphylaxis) to any component of Prevenar 13 or any&#xD;
             diphtheria toxoid-containing vaccine.&#xD;
&#xD;
          -  Recent vaccination defined as any vaccination administered to subjects within 7 days&#xD;
             of enrolment.&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  Limitations of care set including not for resuscitation, not for readmission to&#xD;
             critical care.&#xD;
&#xD;
          -  Residence in a nursing home, long-term care facility, or other institution, or&#xD;
             requirement of semiskilled nursing care. (An ambulatory subject who was a resident of&#xD;
             a retirement home or village is eligible for the trial.)&#xD;
&#xD;
          -  As the IMP is administered intra muscularly, coagulopathy defined as platelet count&#xD;
             less than 50 x 109/L and/or International Normalized Ratio (INR) greater than 1.3. For&#xD;
             this exclusion criteria bloods taken within 72 hours of screening are valid. If these&#xD;
             standard of care blood results are not available, then these should form part of the&#xD;
             screening bloods for assessing eligibility.&#xD;
&#xD;
          -  Splenectomy (previous or in the current admission)&#xD;
&#xD;
          -  Diagnosis of pneumococcal sepsis in the current admission&#xD;
&#xD;
          -  APACHE II score defined Immune deficiency or suppression, defined as presence of 1 or&#xD;
             more of the following conditions:&#xD;
&#xD;
          -  Documented human immunodeficiency virus (HIV) infection at any time-point pre-trial.&#xD;
             If previous results are not available and/or current admission is not due to HIV&#xD;
             infection, these patients do not need new testing and are considered eligible for the&#xD;
             trial.&#xD;
&#xD;
          -  leukaemia (presence defined as having been treated by or been eligible for treatment&#xD;
             by radiotherapy and/or chemotherapy within the last 5 years)&#xD;
&#xD;
          -  lymphoma (presence defined as having been treated by or been eligible for treatment by&#xD;
             radiotherapy and/or chemotherapy within the last 5 years) Hodgkin disease (presence&#xD;
             defined as having been treated by or been eligible for treatment by radiotherapy&#xD;
             and/or chemotherapy within the last 5 years)&#xD;
&#xD;
          -  multiple myeloma (presence defined as having been treated by or been eligible for&#xD;
             treatment by radiotherapy and/or chemotherapy within the last 5 years)&#xD;
&#xD;
          -  malignancy (defined as presence of any malignancy that had been treated by or had been&#xD;
             eligible for treatment by radiotherapy and/or chemotherapy within the last 5 years)&#xD;
&#xD;
          -  chronic renal failure (defined as receipt of renal dialysis or transplant) or&#xD;
             nephrotic syndrome&#xD;
&#xD;
          -  receipt of immunosuppressive therapy, including steroids, within 3 months of study&#xD;
             vaccine administration (For corticosteroids, prednisone or equivalent 0.5 mg/kg/day&#xD;
             for 14 days or longer. Inhaled, intra- articular, and topical steroids are not&#xD;
             considered immunosuppressive).&#xD;
&#xD;
          -  Receipt of an organ or bone marrow transplant with ongoing immunosuppressive&#xD;
             medications. Failed previous transplant patients not currently on immunosuppression&#xD;
             are eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manu Shankar-Hari, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust and King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noelia Pitrelli, MPhil</last_name>
    <phone>02071887188</phone>
    <phone_ext>53378</phone_ext>
    <email>noelia.pitrelli@gstt.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joanne Palmer, MSc</last_name>
    <phone>02071887188</phone>
    <phone_ext>53378</phone_ext>
    <email>Joanne.PalmerJoyce@gstt.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Belfast Health and Social Care Trust</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof Danny McAuley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Charlotte Summers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Timothy Walsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital NHS Foundation Trust</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Ben Creagh-Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr David Brealey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manu Shankar Hari, MD,PhD,FFICM</last_name>
      <email>manu.shankar-hari@kcl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Phil Hopkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Tim Felton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aneurin Bevan University Health Board</name>
      <address>
        <city>Newport</city>
        <zip>NP20 2EF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Tamas Szakmany</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Matthew Rowland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospitals NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr David Pogson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Tyneside and Sunderland NHS Foundation Trust</name>
      <address>
        <city>Sunderland</city>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Anthony Rostron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taunton and Somerset NHS Foundation Trust</name>
      <address>
        <city>Taunton</city>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Richard Innes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

